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The Hippo pathway is a highly conserved signaling pathway responsible for the 
regulation of cellular growth, proliferation and apoptosis. The Drosophila pathway is made up of 
four key proteins Salvador, Hippo, Warts and Mats (Salvador, MST1/2, Lats1/2 and Mob in 
mammals, respectively). At the heart of the signaling cascade are the two core kinases 
Hippo(MST) and Warts(Lats). In order for the pathway to function both of these kinases must be 
phosphorylated and active. Ultimately, Hippo(MST) will phosphorylate Warts(Lats). Once 
phosphorylated, Warts(Lats) is active and proceeds to phosphorylate its target Yorkie(YAP). 
Phosphorylation of Yorkie(Yap) sequesters the transcriptional co-activator from the nucleus 
leading to a downregulation of pro-growth genes. The function of the Hippo pathway core 
proteins in cultured cells can be monitored using luciferase-based reporter assay where luciferase 
signal is a proxy for Yorkie/YAP localization.  I have adapted existing protocols to use this assay 
in both human (HEK293T) and insect (S2) cell lines in the Kavran Lab.  Once established, I used 
the luciferase assay to help elucidate the role of the linker region and phosphorylation sites of 
MST2 in kinase activity, define the minimal functional unit of Lats2, validate the biological 
significance of cysteine 624 in Hippo, and learn about the role of SARAH domains in protein 
binding and activity. Additionally, preliminary work has been started to investigate the 
“hierarchy” of SARAH domains and to validate the SARAH domain interactions of dSalvador 
required for homodimer formation.  
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Preface 
 Optimization of Techniques for Visualizing Protein Functionality in Cell Culture has 
been written to fulfill the graduation requirements for a Masters in Science from the department 
of Biochemistry and Molecular Biology at the Johns Hopkins Bloomberg School of Public 
Health. The research basis of this thesis was conducted in Dr. Jennifer Kavran’s lab between July 
of 2016 to April of 2018. 
 My work was undertaken under the supervision and instruction of Dr. Kavran in order to 
establish cell culture and protocols for various cell based assays. The ultimate goal of these 
protocols is to provide experiments that can be used to recapitulate in vitro protein and 
biophysical data in the context of a cellular environment. Through Dr. Kavran’s continual 
support and teaching I was ultimately able to optimize an easily used and reproducible luciferase 
reporter assay to examine Hippo pathway proteins in cell culture. I am incredibly grateful for all 
that Dr. Kavran has done for me and owe her a great debt of gratitude. 
 Additionally, I would like to thank all of the members of the Kavran lab for their help in 
establishing assays, their continual insights and knowledge, and for creating a wonderful and 
hospitable lab environment. The last two years have been fun and exciting because of Dr. Thao 
Tran, Leah Cairns, Thomas Koehler, Yoo Jin Kim and all of the multiple graduate rotations 
students that have come through the lab. Last, but certainly not least, I would also like to thank 
Dr. Barry Zirkin for his insights throughout the last two years and for agreeing to be the second 
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The Hippo Pathway 
The Hippo pathway has emerged as a critical regulator of cellular maintenance, 
proliferation and apoptosis.  However, dysregulation of the pathway leads to tumorigenesis. 
Recently, multiple studies have demonstrated that the Hippo pathway is a potent driver of 
oncogenesis in lung, breast, colorectal and liver cancers 1-5. It is important to note that there is 
very little evidence that somatic mutations within the Hippo pathway are common causes of 
tumor formation.  Rather, it appears that within the cancer environment, the Hippo pathway 
becomes dysregulated and drives further progression of disease. To better understand why this 
occurs, more needs to be known about the biochemical interactions of Hippo pathway proteins.   
First discovered in Drosophila, and named for the hippopotamus looking overgrowth 
phenotype, the Hippo pathway is now known to be highly conserved across multiple species 6-8. 
At the center of the Drosophila pathway are four key proteins, Salvador, Hippo, Warts and Mats 
(Salvador, MST1/2, Lats1/2 and Mob).  These proteins form the core of the kinase cascade that 
regulates the cellular localization of Yorkie (YAP in mammals) 1,6.  Phosphorylation of the 
transcriptional co-activator, Yorkie (YAP), prevents translocation to the nucleus. In the absence 
of phosphorylation, Yorkie (YAP) translocate to the nucleus and interact with their binding 
partners SCALLOPED(TEAD). Interaction with these transcription factors leads to the 
propagation of pro-growth and proliferation signals 5,9-11. 
At the heart of the Drosophila Hippo pathway is the regulatory kinases, Hippo and Warts. 
These two kinases make up the regulatory cascade that ultimately phosphorylates Yorkie and 
prevents it from binding with its transcription factor, SCALLOPED 6,7,11. The activity of Hippo 
and Warts is modulated by additional adapter proteins that associate with the kinase proteins. 
The first adapter protein of particular interest to our lab is the Drosophila form of Salvador 
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(dSalvador) which acts to stimulate the activity of Hippo. While the mechanism by which 
dSalvador stimulates Hippo kinase activity is not exactly known, it is hypothesized it does this 
through stabilizing the complex of phosphorylated Hippo with Warts leading to increased 
pathway activity 7,12. The second protein of interest to our lab is Drosophila RassF (dRassF). 
dRassF has the opposite effect as dSalvador. dRassF preferentially binds un-phosphorylated, 
inactive, Hippo and prevents it from forming the homodimer required for activation 13. 
Interestingly, when you look at the interaction of the mammalian orthologues of Hippo (MST) 
and RassF(RassF5), RassF5 appears to have the reverse effect, stimulating MST activity 14,15. 
Our lab is interested in better understanding more about these interactions between Hippo, 
dSalvador, and RassF. Additionally, the protein structure of dSalvador is still not well 
understood and we are working to obtain a protein structure and crystallographic studies. 
In the mammalian Hippo pathway, the central cassette is made up of the two kinases, 
MST1/2 and Lats1/2 16-19. Like the Drosophila pathway, these two kinases are modulated by 
adapter proteins in particular human Salvador and Mob1 20,21. MST1/2 responds to upstream 
signals and begins the kinase cascade. To become activated, MST must form a homodimer 
through its SARAH domain and auto-phosphorylate itself 12,15,22. Once activated, MST 
undergoes conformational changes that allow for Mob1 binding and phosphorylation 23. Active 
MST additionally, phosphorylates Salvador. Once phosphorylated both Salvador and Mob1 help 
in propagating the kinase cascade by promoting association of MST and Lats 23,24. MST then 
phosphorylates Lats. Once phosphorylated, Lats is active and can phosphorylate its target YAP, 
sequestering the transcriptional co-factor and marking it for degradation 8,10,19,25. While the 
physiological activity of the mammalian Hippo pathway has been thoroughly studied, the 
biophysical interaction and protein structures of the pathway are less well understood. In 
 3 
particular, our lab is interested in determining protocols for protein crystallization of the core 
kinases, Lats and MST. Additionally, we hope to discover more about the interactions between 






















Optimization of luciferase reporter assay 
Introduction 
Background of the luciferase reporter assay 
 In order to test the functionality, of different variants of Hippo pathway components in 
cells, The Kavran Lab was interested in optimizing a Dual-Luciferase® Reporter Assay System 
(Promega Corporation) protocol 26,27. By comparing luciferase results between wild type and 
mutated proteins, we could establish a reliable readout of their kinase activity in either 
Drosophila and mammalian cells.  
The luciferase assay is an ideal tool for examining protein function in cells because it is a 
relatively simple experiment and can be easily adapted to any signaling pathway that ultimately 
controls transcription. This assay uses the bioluminescence of the firefly luciferase protein as a 
reporter for protein expression levels. The level of luciferase luminescence is proportional to its 
level of protein expression 28-30. There are multiple forms of the luciferase protein.  In our 
reporter assay we use the forms isolated from the firefly (Photinus pyralis) and Renilla (Renilla 
reniformis). Because these two proteins are distinct, this allows us to use one protein, firefly 
luciferase, as a reporter for transcriptional regulation and the other, Renilla luciferase, as the 
internal control for the experiment 30. For ease of explanation, throughout the rest of this paper, 
firefly luciferase will be referred to as “luciferase” and Renilla luciferase as “Renilla.” More 
explanation will follow on the need for the Renilla internal control. 
Expression of firefly and Renilla luciferase  
 The luciferase gene can be put under the control of a promoter that is responsive to a 
gene, or genes, of interest. In our system, we use a Gal-4-upstream activating sequence (UAS) 
promoter fused to the luciferase gene and Gal-4 DNA binding domain (Dbd) fused to Yorkie 
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(Drosophila system) or TEAD (mammalian system). This level of control over the expression of 
the luciferase gene allows for easy visualization of the activity of the protein, or proteins, of 
interest 29.  
Since there is variability in transfection from well to well, an internal control must be 
added to the assay to account for this variation. A plasmid encoding a second luminescent 
protein that will be under the control of a constitutive promoter is also co-transfected into the 
cells. The luminescence from this protein, Renilla, reports on the transfection efficiency and can 
then be used to normalize signal between different wells by accounting for any variation 
resulting from differing transfection efficiency, cell number, or cell lysis efficiency. Classically, 
the Renilla form of luciferase is used as this internal control 30,31. In our protocol, to achieve 
constitutive activity, Renilla was cloned into an expression vector with a SV40 promoter. 
Ultimately, there are a lot of factors influencing variation with in a single replicate of a luciferase 
assay let alone across multiple experimental replicates performed on separate days. Without this 
internal Renilla control, it would be much harder to interpret trends and results. 
Luciferase procedure 
A typical luciferase experiment consists of three stages, transient transfection of cells, 
cell harvesting followed by cells lysis, and reading the luciferase levels of the cell lysates with a 
luminometer. While the first two steps of the assay can be tricky, they are not unique to a 
luciferase assay. Indeed, transient transfections and harvesting cells for their cell lysate are used 
in a multitude of molecular biology experiments. For that reason, I will spend less time dedicated 
to the explanation of the underlying principles of those techniques. However, the detection of 
luminescence for a luciferase assay is pretty unique to this kind of experiment and does require 
further explanation. 
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As previously mentioned, having two distinct luminescent signals is the foundation of the 
luciferase assay. Because the firefly and Renilla forms of luciferase are derived from different 
species, they require different substrates to illuminate 30,31. This distinction makes it possible to 
discriminate between each protein’s bioluminescence within the same sample. To create 
luminescence, both versions of the luciferase protein used in our protocol must be reacted with 
their specific substrate. This procedure is done following the protocol set out by the 
manufacturer of the substrates, Promega Corporation.  First, Luciferase Assay Reagent II 
(LARII) (Promega Corporation) will be added to the cell lysate. This substrate will react with the 
firefly form of luciferase, releasing light. The luminometer will record the intensity of this light 
and give it a numerical value. The reaction will then be quenched. Second, Stop & Glo® Reagent 
(Promega Corporation) will react with the Renilla form of luciferase and again the luminescent 
intensity will be recorded 30.  
Mammalian and Drosophila Luciferase 
Our mammalian protocol for the luciferase reporter assay focuses on four components of 
the Hippo pathway, mammalian Ste20-like kinase (MST1/2), hSalvador, large tumor suppressor 
kinase (Lats1/2) and Mob1. These proteins make up the central regulatory cassette in the 
pathway 22,24,32. MST activation leads to the phosphorylation of Lats. This turns on Lats activity, 
allowing it to phosphorylate its target Yes-associated protein (Yap). Phosphorylation of Yap 
prevents its translocation into the nucleus and marks it for degradation. Therefore, it is unable to 
interact with its transcriptional binding partner TEAD 1,7,25. However, in the absence of Lats 
phosphorylation, YAP is able to translocate to the nucleus and bind to TEAD, turning on a whole 
host of pro-growth genes 1,5.  
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In the context of our luciferase assay, the results of Hippo pathway activity are seen 
through it phosphorylation state of YAP. When the Hippo pathway is on, Lats will phosphorylate 
YAP. This prevents YAP from interacting with TEAD. As previously described, TEAD has been 
fused to a Gal-4-Dbd. Without the interaction between YAP and TEAD, the Gal-4-Dbd does not 
bind to the Gal-4-UAS and luciferase is not transcribed. When Hippo pathway activity is off, 
YAP is able to associate with TEAD, leading to the Gal-4-Dbd binding to the Gal4-UAS and 
transcription of luciferase is activated. What this will ultimately mean is we expect to see low 
luciferase luminescence values when the Hippo pathway is on and high values when the pathway 
is off. 
The Drosophila and mammalian luciferase reporter assays are based upon the same 
principle. They both use the core Hippo pathway components to ultimately phosphorylate their 
downstream targets, in Drosophila, Yorkie and in mammals, YAP 6,7. For the Drosophila 
reporter assay, a Gal-4-DNA binding domain (Gal-4-Dbd) is fused to Yorkie. In the absence of 
Hippo pathway proteins, Yorkie is not phosphorylated, allowing the Gal-4-Dbd to interact with 
the Gal-4 promoter fused the luciferase gene and promoting gene transcription. Conversely, 
when all of the Drosophila pathway components, Hippo, Warts, Mats and dSalvador are 
transfected into the cells, you get a representation of Hippo pathway activity turned on. In this 
case, the kinase cascade ultimately phosphorylates Yorkie and prevents the Gal-4-Dbd from 
binding to the Gal-4-UAS linked to luciferase 7,33,34.  
Research Question 
Previous experiments have shown that co-transfecting members of the Hippo pathway 
into a luciferase system as described above does ultimately lead to the phosphorylation 
Yorkie/YAP and prevents the luciferase protein from being transcribed 10,35,36. These results 
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suggest it is possible to adapt this assay to report on the function of variants of dSalvador, Hippo, 
MST and Lats. Additionally, previous work showed that MST alone could reduce luciferase 
expression levels by approximately sixty-fold and Lats (Warts) alone could reduce luciferase 
expression levels approximately one hundred-fold 9,10,35.  
Currently in our lab we have projects examining protein interactions involving dSalvador, 
Hippo and dRassF, the minimal functional unit of Lats2 and the linker region of MST2. 
However, the bulk of this work has been using in vitro studies with purified protein. In order to 
confirm our in vitro findings in a cellular context and show the biological significance of our 
work, we wanted to establish protocols for cell based assays. We proposed adapting the 
luciferase assay to both mammalian and Drosophila cells as a tool in our ongoing projects to 
examine protein function.  We were especially interested in the results showing that a single 
Hippo pathway component was sufficient enough to significantly reduce luciferase expression 
compared to the positive control. Based on these results, using a luciferase assay, we would be 
able to study individual proteins instead of having to test them in the context of all the Hippo 
pathway components 10,35,36. However, at the inception of this project there was not a protocol for 
cell culture in the lab, let alone a luciferase assay. Because of this, the entire protocol from cell 





To begin experiments, we needed to establish the linear detection range of the 
luminometer. We used purified luciferase protein (Promega Corporation) in decreasing ten-fold 
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dilutions reacted with stock manufacturer LAR substrate at 1x concentration (Promega 
Corporation) (Figure 1A). We also wanted to determine the optimal concentration to use of the 
commercial substrates. During my previous work in the Camargo lab I had been successful in 
using stock manufacturer substrate diluted 3-fold with PBS. To evaluate the efficacy of diluted 
substrate, the same ten-fold dilution of purified luciferase protein was reacted with 1:3 diluted 
substrate. There was no difference in detection efficiency between diluted and undiluted 
substrate (Figure 1A). Using Graphpad Prism7, a line was fit to all the data points and we 
determined that the linear range of detection for the luminometer was between 100 and 10^6 
units (Figure 1A).      
Optimal transfection reagent and cell type 
To find the transfection reagent most suitable for our assay we ran a test luciferase assay 
comparing the efficiency of each of the transfection reagents present in the lab on HEK293 cells 
(American Type Culture Collection (ATCC)). Cells were transiently transfected with either 
luciferase and Renilla or luciferase, Renilla and YAP using either Effectene (Qiagen), Fugene 6 
(Promega Corporation), Lipofectamine LTX (Thermo Fisher Scientific) and PolyJet (SignaGen 
Laboratories) each according to the manufacturer’s instructions. Each transfection reagent has an 
increase in luciferase expression in the positive control (with YAP) compared to the luciferase 
and Renilla alone (Figure 1B.). However, the luciferase activity from cells transfected with 
PolyJet, Effectene and Fugene 6 is ten to twenty-fold higher than the cells transfected with 
Lipofectamine LTX, indicating those were superior transfection reagents for this assay (Figure 
1B).  
To identify the optimal cell type for our protocol we used a luciferase assay to compare 
HEK293 cells (ATCC) and HEK293T cells (ATCC).  HEK293T are a derivative of HEK293 
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cells that are “highly transfectable and contain the SV40 t-antigen (ATCC).” HEK293T cells 
have ten-fold more luciferase expression levels compared to HEK293 cells using PolyJet 
transfection reagent (Figure 2B).  
Using fluorescence activated cell sorting (FACS), with the assistance of the Holland lab, 
we checked the transfection efficiency of HEK293T and HEK293FT cells with a reporter green 
fluorescent protein (GFP) plasmid using PolyJet (Figure 3). Additionally, as a transfection 
control, replicates of our experiment were performed by the Holland lab using their normal 
transfection reagent, Transfection Grade Linear Polyethylenimine Hydrochloride Max (PEI) 
(Thermo Fisher Scientific). When tested, there was no significant difference in GFP expression 
between HEK293T and HEK293FT cells (Figure 3). Interestingly, there was less than a fold 
change in efficiency between PolyJet and PEI (Figure 3).  
Testing frozen cell lysate 
In my previously lab work in the Camargo Lab we had frozen luciferase assay cell lysate 
in order to accommodate scheduling. When we compared assay results between fresh and frozen 
cell lysate we never saw any difference. However, before adopting this procedure, we wanted to 
validate that in our hands we would also not see a difference. To do this, a luciferase assay was 
run using lysate from cells transfected with either luciferase and Renilla, luciferase, Renilla, and 
YAP, or luciferase, Renilla, YAP and Hippo pathway proteins using PolyJet transfection reagent 
that was either fresh or previously frozen (Figure 4). When comparing the exact same 
experimental samples, fresh or previously frozen, no difference in luciferase activity was noted. 
This confirmed that samples could be frozen and luminescence recorded at a later time (Figure 
4). 
Optimization of plasmid ratios and incubation times 
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After performing these initial luciferase assays we noticed that when Hippo pathway 
components were transfected, we did not see the previously published reduction in luciferase 
expression (Figure 2C) 10,36. In order to try to rectify this issue, we tested different incubation 
times post transfection (Figure 5). Cells were transfected with plasmids encoding luciferase and 
Renilla, luciferase, Renilla, and YAP, or luciferase, Renilla, YAP and Hippo pathway proteins 
using PolyJet transfection reagent. They were then harvested and lysed at either 48 or 72 hours. 
Unfortunately, there was no change between these time points (Figure 3A). Additionally, we 
tested cells transfected with either luciferase and Renilla, luciferase, Renilla, and YAP, or 
luciferase, Renilla, YAP and MST or Lats using PolyJet at 24, 48, 72 or 96 hours. Again, there 
was no change in luciferase expression between different time points (Figure 5C). Lastly, an 
experiment was run at two different time points in which the amount of YAP was changed 
compared to our original protocol (Figure 5B). Cells were transfected with either luciferase, 
Renilla, and YAP (14ng or 70ng), or luciferase, Renilla, YAP (14ng or 70ng) and Hippo 
pathway proteins using PolyJet transfection reagent. After either 24 or 48 hours cells were 
harvested and lysed. By reducing the amount of YAP, there appears to be a half-fold reduction in 
relative luciferase activity in the samples with Hippo pathway components added (Figure 5B). 
Based upon Zhao et. al. 2007, the major players in the luciferase reporter assay are the 
core Hippo kinases, MST and Lats 10. With that in mind, we tested to see either kinase alone 
would be sufficient to inhibit luciferase activation. Cells were transfected with either luciferase 
and Renilla, luciferase, Renilla, and YAP, or luciferase, Renilla, YAP and MST or Lats using 
PolyJet.  In order to try and saturate the system the amount of each kinase was significantly 
increased from the original 50ng protocol to either 250ng or 500ng. As previously mentioned, 
the cells were harvested at four time points, 24, 48, 72 and 96 hours. Increasing MST or Lats did 
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not inhibit relative luciferase activity. When compared to the positive control (with YAP) there 
was less than a fold reduction in expression levels (Figure 5C).  
Continued optimization of cell lines and transfection reagents 
Because we had not been able to reproduce previously published results with the cells 
and reagents in lab, we bought new HEK293T cells (ATCC) and a new transfection reagent 
Lipofectamine 2000 (Thermo Fisher). I had worked previously with Lipofectamine 2000 in the 
Camargo Lab and had never had transfection issues when using it. We compared newly 
purchased cells to the cells already in lab, transfecting them with either luciferase and Renilla, 
luciferase, Renilla, and YAP, or luciferase, Renilla, YAP and Hippo components using either 
PEI or Lipofectamine 2000. Cells transfected with luciferase, Renilla, YAP using Lipofectamine 
2000 have a two hundred-fold increase in relative luciferase compared to cells transfected using 
PEI (Figure 6A and 6B). Additionally, when comparing the cells purchased from ATCC to the 
HEK293T cells already in culture in the lab, there is a seventy-fold greater reduction in 
luciferase expression when Hippo components are added to luciferase, Renilla and YAP, (Figure 
6A and 6B).  
Optimal luciferase conditions 
Through optimizing the amount of each plasmid being transfected for our luciferase 
assay, we were ultimately able to achieve between a sixty and two hundred-fold reduction in 
relative luciferase activity when Hippo components are added (Figure 7A and 7B).  This was the 
result of adjusting the amount of Gal-4-UAS-Luciferase that we transfected. By increasing the 
amount of plasmid encoding for the luciferase protein and reducing the amount of plasmid 
encoding TEAD, our results began to reproduce previously published data. We were also able to 
replicate the sixty-fold reduction in luciferase expression by MST when compared to luciferase, 
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Renilla, and YAP. However, this difference in not statistically significant (Figure 7) 10.  
Unfortunately, we could not replicate the previously published results of a one hundred-fold 
reduction of relative luciferase activity by Lats alone (Figure 7) 10. 
Drosophila Luciferase 
 To test the Drosophila reporter assay, S2 cells were transfected with luciferase and 
Renilla (null control), luciferase, Renilla and Yorkie (positive control) using Fugene6. The two 
core kinases Hippo and Warts were also transfected, either alone or together. Experiments with 
Hippo alone, Warts alone, and Hippo with Warts all reduced the relative luciferase activity to 
levels within error of the null control (Figure 8A). The reduction of luciferase expression to the 
null control signifies that Hippo and Warts’ kinase activity is enough to completely prevent 
Yorkie from driving luciferase transcription. This result matches previously published work 7,35. 
While our results for Hippo and Warts activity are similar to published work, relative luciferase 
activity in the positive control was about six-fold lower than previously published. While this 
difference is not large in context of the mammalian luciferase assay, in the Drosophila assay, the 
relative luciferase activity seen in the positive control maxes out around fifteen to twenty-fold 
higher than the null control.  
Optimization of plasmid ratio 
 In order to increase the relative luciferase activity for the positive control, the amount of 
Yorkie used in our standard protocol was increased in two-fold amounts of Yorkie, from 25ng to 
200ng. To make sure that the amount of Yorkie would not saturate the system, experiments with 
luciferase, Renilla, increasing amounts of Yorkie and constant amounts, 50ng, of Hippo and 
Warts were run alongside the experiments with luciferase, Renilla and the increasing amounts of 
Yorkie. The increased amounts of Yorkie (50ng, 100ng, or 200ng) have approximately seven-
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fold higher luciferase expression levels than the 25ng used in the original protocol (Figure 8B). 
These expression levels match previously published results 7,35 Complete reduction of luciferase 
expression by Hippo and Warts was seen in experiments conducted with 25ng, 50ng and 100ng 
of Yorkie with Hippo and Warts (Figure 8B). However, when 200ng of Yorkie were transfected 
into S2 cells, there was no longer a significant reduction in relative luciferase activity when 
compared to the positive control (Figure 8B). This signifies that at 200ng of plasmid encoding 
Yorkie, the system becomes saturated and Hippo and Wart’s kinase activity is no longer great 
enough to inhibit luciferase activation. 
Optimization for dSalvador 
One of our research questions in the Kavran Lab is how dSalvador, in particular the 
extended N-terminal region of dSalvador’s SARAH domain impacts Hippo signaling. Therefore, 
during Drosophila assay optimization it was important to make sure that our protocol was 
optimized to examine dSalvador function. To establish a protocol for monitoring the effects of 
dSalvador on Hippo pathway signaling, S2 cells were transfected with the null control, positive 
control, luciferase, Renilla, Yorkie and dSalvador alone or with dSalvador co-expressed with 
Hippo, or Hippo and Warts using Fugen6. When dSalvador was added alone it resulted in a two 
hundred-fold reduction of luciferase expression compared to the positive control but did not 
result in the complete reduction of relative luciferase activity seen in previous experiments with 
Hippo or Warts (Figure 9A). To try and get the complete reduction of relative luciferase activity, 
the experiment was repeated but with 200ng of plasmid encoding for dSalvador instead of the 
50ng previously used. Again, there was a significant, two hundred-fold reduction in activity but 





Mammalian cells, HEK 293, 293T and 293FT were cultured in Dulbecco's Modified 
Eagle Medium (Gibco) with 2mM L-Glutamine (Gibco) and 5% heat inactivated Fetal Bovine 
Serum (FBS) (VWR). After research and additional testing, we determined that a synthetic form 
of FBS could be used in culture media and switched the lab over to FBEssence (FBE) (VWR). 
Culture chamber was maintained at 37oC with 5% CO2. All mammalian Luciferase transfections 
were performed in 12 well cell culture plates seeded with 5*10^4 cells in 1mL of culture media. 
Cells were seeded and transfected on the same day for all mammalian reactions. After 48 hours 
cells were harvested and lysed. Cell lysate was then used for the luciferase assay. 
Drosophila S2 cells were cultured in Schneider’s Insect Medium (Gibco) with 10% heat-
inactivated FBS. S2 cells cannot be grown in media with FBE. The culture chamber was 
maintained at 28oC without CO2. All Drosophila luciferase experiments were performed in 12 
well cell culture plates seeded with 1*10^5 cells in 1mL of culture media. Cells were seeded on 
day 0 and transfected on day 2. 72 hours after transfection cells were harvested and lysed.  
Mammalian and Drosophila Luciferase Protocol: 
 Transfections for both mammalian and Drosophila cells were performed following a 
standard protocol (Appendix 1). For each luciferase experimental condition, two or three wells 
(depending upon well availability) were transfected in replicate from the same master mix of 
transfection reagent and DNA. These experimental replicates are in order to prevent any 
significant transfection variation that could confound results. In order to obtain publication level 
results, multiple biological replicates across multiple days are needed but for many of the early 
test luciferase assays only the two experimental replicates were obtained.  
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 After transfection, cells were cultured according to a standard protocol (Appendix 1). At 
the appropriate time, cells were harvested and lysed. Luciferase assay was then performed using 
the appropriate commercially available substrates and a H1 Synergy (Biotek) luminometer for 
detection of luminescence (Appendix 1). 
The results from the luminometer are raw intensity values and do not immediate give us 
much information about our proteins of interest. In order to better understand the data, we first 
divide the raw “luciferase” value by the corresponding “Renilla” value for each replicate which 
will be called the “ratio”. As previous mentioned, this takes into account any variations across 
wells. Next, the ratio values for the positive control and our experimental wells will be divided 
by the ratio value of the null control. In our protocol, the null control will be wells transfected 
with only luciferase and Renilla. The ratio value from the first well of the null control duplicate 
will be used to divide the ratio value for the first well of the positive control duplicate and 
continuing to the experimental wells. The ratio value of the second well of the null control will 
be used in the same manner. The results of this should give the null control a value of one with 
the positive control and experiments with a positive number. That number is plotted as relative 
luciferase activity. 
 Graphs were plotted using Graphpad Prism7 using either an XY, column or grouped 
graph depending on the experimental parameters. The Y-axis correlates to the relative luciferase 
expression given in units, as previously described. The X-axis represents the experimental 
conditions of the results in that column of the graph. To calculate p values, the appropriate 
statistical test (t-test, one-way ANOVA, two-way ANOVA, etc.) was performed using the 
analysis tool in Graphpad Prism7. 
Fluorescence-activated Cell Sorting 
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 6 well plates were seeded with 3*10^5 mammalian cells in 2mL of culture media. Cells 
were transfected with 2ug of empty pcDNA or pcDNA-GFP (plasmid code 112, Kavran Lab) 
plasmid. After 48 hours, the transfected cells were harvested from their plates. Due to the 
adherent nature of HEK293T and HEK293FT and in order to be as gentle as possible so not to 
lyse the cells, 0.05% Trypsin-EDTA (Gibco) was used to remove the adherent cells instead of 
mechanical force. To do this Trypsin was pre-warmed to 37oC in a water bath, media was 
removed from the cells and 0.5mL of Trypsin was added to each well. The plate was then 
returned to the incubator for 2 minutes, or until cells easily lifted off the plate. 1mL of 
DMEMF12 with 5% FBE and 2mM L-glutamine was then added to each well in order to 
neutralize the Trypsin. Then the cell containing media was transferred to 1.5mL Eppendorf 
tubes. Tubes were then centrifuged at 1200*g for 5 minutes. The supernatant was removed and 
the cell pellet was gently washed with 1mL of Phosphate buffered Saline (PBS). This was then 
spun down again and supernatant aspirated. Finally, the cells were re-suspended in 2mL of PBS, 
transferred to appropriate FACs tubes and sorted by a Fluorescence-activated cell sorting 
machine. GFP gates were set against cells transfected with an empty plasmid. 
Transfection reagents 
 Effectene (Qiagen), Fugene 6 (Promega Corporation), Lipofectamine 2000 (Thermo 
Fisher Scientific), Lipofectamine LTX (Thermo Fisher Scientific), Transfection Grade Linear 
Polyethylenimine Hydrochloride (PEI) Max (Thermo Fisher Scientific) and PolyJet (SignaGen 
Laboratories). 
Mammalian Plasmids 
 pcDNA-GFP (MacroLab), pcDNA3-Myc-Lats, pcDNA3-HA-Mob, pcDNA3-HA-Mst2, 
pcDNA3-HA-hSalvador, pcDNA3-CMV-Yap2, pCMX-Gal4-Tead4, pGL4.31-Gal4-UAS-
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Luciferase, pRL-SV40-Renilla. All mammalian luciferase plasmids were obtained from the 
Addgene repository. Plasmid codes can be found in the plasmid table for the final protocol. 
Drosophila Plasmids 
 pAc-Gal4Dbd-YkiV5 (Irvine Lab), pUAST-Gal4-Luciferase (Irvine Lab), pRL-SV40-
Renilla (Irvine Lab), pAWF-dHpo (Tapon Lab), pAWF-dMats (Tapon Lab), pAMN-dSav 
(Tapon Lab), pAWF-dWts (Tapon Lab) and pAWF-dRassF (Tapon Lab). Plasmid codes can be 




There was not very much cell culture to speak of in lab when protocol optimization 
began. Thanks to Dr. Kavran’s previous lab we had many of the needed reagents to make media 
and maintain the cell cultures. While there were not many issues with the reagents, there were 
some challenges when it came to the equipment like determining the detection limits of the 
luminometer (Figure 1A).   
The two biggest challenges to optimization though turned out to finding the optimal cell 
line and transfection reagent. Originally, we had HEK293 cells in culture but we quickly 
discovered their transfection efficiency was not good enough (Figure 2B). This left us using 
HEK293T and HEK293FT cells. Both these cells are optimized for transfections over the normal 
HEK293 cells. When they were compared to each other there was no difference in transfection 
efficiency of HEK293T and HEK293FT cells (FACS DATA). Ultimately though because we 
could not replicate previously published result, we purchased brand new HEK 293T cells from 
ATCC. The new HEK293T cells proved to be able to be transfected efficiently and with 
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optimization of other variables ultimately produced the results we were hoping for (Figure 5B 
and 6). 
Besides determining the right cell line, finding the optimal transfection reagent was the 
biggest road block to our experiments. In particular, the results of the FACS experiment (Figure 
3) inadvertently caused a significant challenge in optimizing the protocol. As a positive control 
in the FACS experiment, we used the transfection reagent that the Holland Lab uses, PEI. PEI is 
significantly cheaper and has an even easier protocol than PolyJet, the transfection reagent we 
were using. As a transfection reagent, it worked great for single plasmids as seen in the FACS 
data and it was assumed that it would work just as well for the luciferase assay (Figure 3). For a 
long time, challenges with cells hid the issue with using PEI for multiple plasmids. Ultimately 
though, through research and reading online science forums it was determined that PEI was not 
efficient at transfecting more than three of four plasmids. This was why we believe there was not 
significant inhibition of luciferase activity when PEI was being used to transfect in all of the 
Hippo pathway components (Figures 6). The same science forums that I had used to find out 
about PEI also gave suggestions about alternative transfection reagents but ultimately, I turned 
the transfection reagent I had used while working in the Camargo lab and I was comfortable 
working with, Lipofectamine 2000 (Thermo Fisher). Immediately, we saw large increases in the 
expression of our proteins following transfection with two to three hundred-fold increases in 
luciferase expression in experiments transfected with Lipofectamine 200 compared to PEI 
(Figure 6).  After a few trial runs, we were able to see results similar to what was previously 
demonstrated (Figure 6 and 7) 10. 
The final part of the puzzle in getting all of our data to match previously published 
results, was finding the right ratios of plasmids to transfect. Our original protocol used a 1:1 ratio 
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of all the plasmids, except for Renilla. From previous work with luciferase assays in the 
Camargo Lab, I knew that Renilla had very good expression and at a 1:1 ratio would not fall 
within the luminometer’s detection range. With that in mind, the original protocol used only 
14ng of Renilla DNA in all of the transfections. It was quickly discovered that the 1:1 DNA ratio 
was maxing out the luminometer detection limits (Figure 2). In Figure 2B it should be noted that 
an experimental value is missing for the HEK293T value in column “2” this a because the 
luciferase value exceeded the detection limit of the luminometer, resulting in an “overflow” 
instead of a numerical value. Additionally, because there was little to no luciferase inhibition 
from the Hippo components, it was hypothesized that the system was being saturated with YAP 
(Figure 2B).  To prevent this, the amount of YAP was reduced to a third of the amount of the rest 
of the plasmids. This allowed for sufficient levels of activity of the Hippo kinases to 
phosphorylate and sequester YAP (Figure 7). In the end, the biggest change to the transfection 
protocol came from a suggestion from a friend of the lab, Chris Cho. He suggested that we 
increase the amount of Gal4-Luciferase and Hippo components being transfected in and reduce 
the amount of Gal4-TEAD. This was based off of his previous experience with luciferase assay 
37. This change finally made it possible to partially reproduce the Zhao et. al. 2007 results 
(Figure 7). 
 Our protocol was ultimately able to reproduce the one hundred to one hundred twenty-
fold luciferase expression reduction seen with all the Hippo pathway components as well as the 
fifty to sixty-fold reduction with MST alone, but we were not able to reproduce the one hundred-
fold reduction from Lats alone that Zhao et. al. 2007 show. With all the Hippo pathway 
components, we can significantly inhibit luciferase expression. Individual proteins show either 
not reduction in luciferase expression or only weak inhibition that is not significant. This means 
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that we do have a protocol where we can test the functionality of our Lats and MST mutants, but 
only in the context of all the other Hippo pathway components. Unfortunately, the dynamic 
range of our results doesn’t provide the space to judge relative activity level. Instead, our 
protocol can only be used to give a binary answer of either the mutant is functional or it is not. In 
the future, optimizing a protocol that allows examination of individual proteins would be ideal. 
Finding a system that relied upon fewer plasmid could further increase our expression levels and 
creating a dynamic range where a single protein could be examined. Additionally, recent 
unpublished work in our lab suggests that our HEK293T cells have a relatively high background 
level of Hippo pathway activity. This could prove to be confounding in our system as we have 
seen that the luciferase assay is fairly sensitive to change and can have wide variation between 
experiments. Switching to an alternative cell line might help to address this problem and further 
optimize our protocol. 
Drosophila Luciferase 
 Unlike the mammalian luciferase reporter assay, our protocol was able to replicate 
previously published result using S2 cells on the first attempt 7. The only major difficulty was 
establishing a culture protocol for our S2 cells. Originally, the media, Grace’s insect media 
(Thermo Fisher) supplemented with 10% FBS, that we used did not work. However, we quickly 
realized that this was not the appropriate media for S3 cells. Upon suggestion from another lab, 
and researching preferred media for S2 cells, we switched our media to Schneider’s Drosophila 
media (Gibco) with 10% FBS. Drosophila culture media must be supplemented with FBS and 
not FBE. When the synthetic form of FBS, FBE, that our lab uses in mammalian media was used 
instead, the S2 cells died.  
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 Preliminary S2 luciferase data showed that our protocol resulted in six-fold (about 50% 
lower) than published data for luciferase expression in the positive control. In order to rectify this 
issue, we tested the amount of Yorkie that could raise our luciferase expression while still 
responding to Hippo and Warts activity. Figure 8B. shows that there was no change in the level 
of luciferase expression between different Yorkie amounts except for when 200ng of Yorkie was 
used. The previous experiment was conducted with 25ng of Yorkie. Since our reduction of 
luciferase expression was complete, we hypothesized that levels of Hippo and Warts were 
saturating the system. As hypothesized, Hippo and Warts were saturating the system. By 
increasing the amount of plasmid encoding Yorkie transfected to 50ng we were able to increase 
our luciferase expression in the positive control almost eight-fold, similar to that of previous 
work 7. We did note that between the 50ng, 100ng, 200ng of plasmid encoding for Yorkie there 
was not change in luciferase expression. This suggests that 50ng of Yorkie was enough to 
saturate the Gal-4 binding site on luciferase and that Yorkie was no longer the limiting factor in 
the system. Due to these results, the protocol was amended to use 50ng of plasmid encoding for 
Yorkie.  
 Since dSalvador alone did not reduce luciferase expression to the desired level, it could 
not be used alone in our protocol however, this was not unexpected. Instead, dSalvador must be 
co-transfected with Hippo in order to reduce luciferase expression to the desired result. This 
would later prove to be a confounding issue. The amount of luciferase reduction seen between 
experiments with Hippo and dSalvador and Hippo alone provides a very small dynamic range. It 
is important to note that in experiments with dSalvador, the luciferase expression level is much 
higher than in other S2 experiments (Figure 8 and 9). This allows for a much larger fold 
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reduction than usual however, it is extremely variable. The elevated level of expression is seen in 

























































































































Figure 1A. The dynamic range of 
luciferase detection
Purified luciferase protein was diluted in 
a ten-fold manner with PBS and then 
reacted with substrate. Using a lumi -
nometer, luminescent emission was 
detected and unit readout was provided. 
Additionally, 1:3 diluted substrate was 
tested for efficacy in comparison with 
manufacturer’s stock. Luminescent 
values were then plotted against the 
known value of purified protein to 
obtain a standard curve. A line was then 
fit to the data to demonstrate the linear 
range of detection of the luminometer. 
Figure 1B. Optimal transfection reagent for luciferase reporter assay
Different transfection reagents were used to transfect i n 10ng of Renilla, 70 ng of Gal4-Luciferase, 70ng 
Gal4-TEAD, and 70ng of Yap1 using either PolyJet, Fugene 6, Lipofectamine or Effectine. After 48 hours 
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Figure 2. Optimization of luciferase reporter assay in 
Hek293 cells
A. Using PolyJet transfection reagent, Hek293 and 
Hek293T cells were transfected with 
Gal-4-Dbd-TEAD, Gal-4-UAS- luciferase, Renilla, 
Yap and Hippo pathway components. After 48 hours 
cells were lysed and luciferase assay was run using cell 
lysate. Luciferase expression was normalized to the 
positive control (1. Luciferase, Renilla, and YAP). The 
black bars represent results from Hek293 cells. The 
grey bars represent results from Hek293T cells.
B. Instead of normalizing to the positive control, the 
same data as A. was normalized to the null control (0. 
Luciferase and Renilla). The null control in our system 
takes into account any endogenous YAP that could 
interact with Gal-4-Dbd-TEAD leading to luciferase 
expression. Of note, column 2 is lacking a value for 
Hek293T cells because the value for the expression 































































Figure 3. Fluorescence Activated Cell Sorting (FACS) of Hek293T and Hek293FT cells
Hek293T cells transfected with empty plasmid enc oding nothing (panel A). Panels B-E were 
transfected with a plasmid that encodes green fluor escent protein (GFP) (plasmid 115, Kavran 
Lab). Panels B and C are Hek293t cells. Panels D a nd E are Hek293FT cells. For panels B and D 
GFP encoding plasmid was transfected using PEI. For panels C and E GFP encoding plasmid was 
transfected using PolyJet.
Cells in the blank controls (Panel A) were used to set sorting gates. All cells to the left of the middle 
line are green fluorescent protein (GFP) negative. A total of 10,000 cells were sorted. ).02% of null 
cells were positive for GFP using the gate setting we chose. Heat map corresponds to the number of 
cells that are present at that fluorescent intensity (re d is high cell number, blue is low cell number). 
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Figure 4. Comparison of luciferase assays 
performed on fresh or previously frozen 
cell lysate
Using PolyJet transfection reagent, 
Hek293 cells were transfected with 
Gal-4-Dbd-TEAD, Gal-4-UAS- lucifer -
ase, Renilla, Yap and Hippo pathway 
components. After 48 hours cells were 
lysed and luciferase assay was run using 
cell lysate. Luciferase expression was 
normalized to the null control (0. Lucifer -
ase and Renilla). The null control in our 
system takes into account any endogenous 
YAP that could interact with 
Gal-4-Dbd-TEAD leading to luciferase 
expression. Lysate was either previously 
frozen or fresh. Black bars represent 
results from fresh lysate. Grey bars 
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Figure 5. Optimal post transfection incubation period 
and determination of ideal plasmid ratios
A. Using PolyJet transfection reagent, Hek293 and 
Hek293T cells were transfected with 
Gal-4-Dbd-TEAD, Gal-4-UAS- luciferase, Renilla, 
Yap and Hippo pathway components. After 24 and 48 
hours cells were lysed and luciferase assay was run 
using cell lysate. Luciferase expression was normal -
ized to the positive control (1. Luciferase, Renilla, 
and YAP). The black boxes represent results from 24 
hours. The empty boxes bars represent results from 
48 hours cells. Error bars represent the standard 
deviation, as calculated by Graphpad Prism7, 
between the two well replicates.
B. To try and find optimal induction of luciferase 
activity, the amount of YAP transfected was varied.  
Cells were then harvested at either 24 or 48 hours 
following transfection. Results were normalized to 
the positive control (luciferase, Renilla and Yap). 
Black boxes represent results from 24 hours. Grey 
boxes represent result from 48 hours.
A. B.
C.
C. Increasing amount, 250ng or 500ng, of the two core kinases, MST  and Lats, were transfected.  After 24, 48, 72 and 96 
hours cells were lysed and luciferase assay was run using cell lysate. Luciferase expression was norm alized to the positive 
control (1. Luciferase, Renilla, and YAP). Black circle represent data from 24 hours. Empty boxes re present data from 48 
hours. Black boxes represent data from 72 hours. Empty circles represent data from 96 hours. Error b ars represent the 











































































































Figure 6. Hek293T cells purchased from 
ATTC and the alternative transfection 
reagent Lipofectamine 2000 increase 
luciferase expression
A. Hek293T cells previously cultured in 
lab were transfected with 
Gal-4-Dbd-TEAD, Gal-4-UAS-lucifer -
ase, Renilla, YAP and Hippo components 
using either PEI or Lipofectamine 2000. 
After 48 hours cells were harvested. 
Results were normalized to the null 
control (luciferase and Renilla). Using 
GraphPad Prism, standard deviation was 
calculated. Error bars represent the 
standard deviation between replicates. 
Black circles represent results from cells 
transfected with PEI. Black boxes repre -
sent results from cells transfected with 
Lipofectamine 2000. 
B. Hek293T cells purchased from ATCC 
were transfected with Gal-4-Dbd-TEAD, 
Gal-4-UAS-luciferase, Renilla, YAP and 
Hippo components using either PEI or 
Lipofectamine 2000. After 48 hours cells 
were harvested. Results were normalized 
to the positive control (luciferase, Renil -
la, and YAP). Using GraphPad Prism, 
standard deviation was calculated. Error 
bars represent the standard deviation 
between replicates. Black circles repre-
sent results from cells transfected with 
PEI. Black boxes represent results from 
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Figure 7. Hippo pathway components inhibit 
luciferase expression
A. First run of new protocol using Lipofect -
amine 2000, new Hek293t cells and plasmid 
ratios. Hek293T cells previously cultured in 
lab were transfected with Gal-4-Dbd-TEAD, 
Gal-4-UAS-luciferase, Renilla, YAP and 
Hippo components using Lipofectamine 
2000. Results were normalized to the null 
control (luciferase and Renilla). Using 
Graphpad Prism7, luciferase expression 
values were plotted. Error bars represent the 
standard deviation between the two repli -
cates of each experimental condition. Statis -
tics calculated in Graphpad Prism (p value 
0.001, n=2).
B. Second run repeating previous experi -



































































































































Figure 8. Optimization of Drosophila luciferase 
plasmids and plasmid concentration 
A. S2 cells were transfected with plasmids encod -
ing for Gal-4-UAS-luciferase, Renilla, 
Gal-4-Dbd-Yorkie, Warts and Hippo using Fugene 
6. Two replicates of each sample were run. Data 
was normalized to the luciferase expression of the 
null control (luciferase and Renilla). Normalized 
data was then plotted and standard deviation deter -
mined using Graphpad Prism7. Statistical analysis 
was performed comparing experiments to the 
positive control (luciferase, Renilla and Yorkie) (p 
value 0.001, 0.003, 0.001, n=2).
**
B.
Using the same protocol as above, 
increasing amounts of Yorkie were 
added to samples with or without 
Hippo and Warts. Experiments run 
with 25ng, 50ng, 100ng and 200ng 
of Yorkie. Two replicates of each 
sample were run. Data was normal-
ized to the luciferase expression of 
the null control (luciferase and 
Renilla). Normalized data was then 
plotted and standard deviation 




























































































Figure 9. Optimization of dSalvador 
in Drosophila luciferase
A. S2 cells were transfected with 
plasmids encoding Renilla, a Gal4-lu -
ciferase, Gal4Dbd-Yorkie, Hippo, 
Warts and 50ng of dSav using 
Fugene6. Two replicates of each 
experiment were obtained. Experi -
mental values were normalized to the 
null control (luciferase and Renilla). 
Normalized values were plotted using 
Graphpad Prism. Error bars represent 
the standard error as determined by 
Prism. Statistical analysis was 
performed comparing experiments to 
the positive control (luciferase, 
Renilla and Yorkie) (p value 0.007, 
0.002, 0.002, n=2).
B. In the same way as above, S2 cells 
were transfected with plasmids 
encoding Renilla, a Gal4-luciferase, 
Gal4DBD-Yorkie, Hippo, Warts and 
200ng of dSav using Fugene6. (p 
value 0.01, 0.0008, 0.0007, n=2).
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Table1. Original mammalian Plasmid Protocol 
Final DNA concentration of 1g of DNA per well. In order to reach 1g of total DNA empty 
pcDNA was transfected in addition to our experimental plasmids. Code refers to the code that the 
Kavran Lab has assigned to the plasmid. Complete list of Kavran Lab plasmids can be found on 
the Kavran Lab Google Drive. 
Code Plasmid Concentration 
90 Gal4-UAS-Luciferase 70ng 
91 pRL-SV40-Renilla 14ng 
92 p2xFlagCMV2-Yap2 70ng 
93 Gal4-Dbd-TEAD4 70ng 
94 pcDNA-HA-Mst2 70ng 
95 pcDNA-HA-Sav 70ng 
96 pcDNA-HA-Mob 70ng 











Table 2. Final mammalian Plasmid Protocol  
 Final concentration of 1g of DNA per well. In order to reach 1g of total DNA empty pcDNA 
was transfected in addition to our experimental plasmids. Code refers to the code that the Kavran 
Lab has assigned to the plasmid. Complete list of Kavran Lab plasmids can be found on the 
Kavran Lab Google Drive. 
Code Plasmid Concentration 
90 Gal4-UAS-Luciferase 100ng 
91 pRL-SV40-Renilla 10ng 
122 p2xFlagCMV2-Yap2 25ng 
93 Gal4-Dbd-TEAD4 75ng 
94 pcDNA-HA-Mst2 75ng 
95 pcDNA-HA-Sav 75ng 
96 pcDNA-HA-Mob 75ng 












Table 3. Original Drosophila Plasmid Protocol 
Final concentration of 0.5g of DNA per well. In order to reach 0.5g of total DNA empty 
pAc5.1 vector was transfected in addition to our experimental plasmids.  Code refers to the code 
that the Kavran Lab has assigned to the plasmid. Complete list of Kavran Lab plasmids can be 
found on the Kavran Lab Google Drive. 
Code Plasmid Concentration 
75 Gal4-Dbd-Ykiv5 25ng 
76 Gal-4-pUAST-Luciferase 75ng 
77 pRL-SV40-Renilla 10ng 
66 pAWF-dHpo 50ng 
68 pAWF-dMats 50ng 
69 pAMN-dSav 50ng 
70 pAWF-dWts 50ng 












Table 4. Final Drosophila Plasmid Protocol 
Final concentration of 0.5g of DNA per well. In order to reach 0.5g of total DNA empty 
pAc5.1 vector was transfected in addition to our experimental plasmids. Code refers to the code 
that the Kavran Lab has assigned to the plasmid. Complete list of Kavran Lab plasmids can be 
found on the Kavran Lab Google Drive. 
Code Plasmid Concentration 
75 Gal4-Dbd-Ykiv5 50ng 
76 Gal-4-pUAST-Luciferase 75ng 
77 pRL-SV40-Renilla 10ng 
66 pAWF-dHpo 50ng 
68 pAWF-dMats 50ng 
69 pAMN-dSav 50ng 
70 pAWF-dWts 50ng 









Understanding SARAH domains and the novel structure of dSalvador 
Introduction 
SARAH Domains 
At the heart of the Drosophila Hippo pathway lies Hippo, one of the pathways core 
kinases, and two adaptor proteins that help modulate Hippo’s activity. These three proteins, 
Hippo, dSalvador, and dRassF all associate through C-terminal SARAH domains (Salvador-
RassF-Hippo). A SARAH domain is a C-terminal alpha helix that facilitates protein binding 
through anti-parallel coiled-coil interactions 38-40. Not only do these SARAH domains facilitate 
the heterodimer formation between Hippo and dRassF, as well as. Hippo and Salvador, they also 
allow the respective proteins to form homodimers. Importantly, the Hippo homodimer formation 
that is required for activation is mediated by its SARAH domain 15,38.   
Human Salvador and MST hetero- and homodimer formation 
 Drosophila Salvador (dSalvador), a scaffolding protein, is known to play a role in the 
activation of Warts by facilitating the association of Hippo and Warts 41. However, there is far 
less understood about the role of human Salvador 42. Recent work has shown that MST (Hippo) 
and the human orthologue of Salvador (also known as WW45) associate with each other leading 
to the phosphorylation of Salvador 12. Like in the SARAH domain interaction of Hippo and 
dSalvador, the association of MST and Salvador is dependent upon the C-terminal coiled-coil 
domains of each protein interacting to form a heterodimer 12. Despite this requirement to form a 
heterodimer between MST and Salvador, the same research showed that the homodimer 
formation of Salvador could be achieved in mutants lacking the C-terminal coiled-coil region. 
The authors hypothesized that the mediator of dimer formation was the tryptophan residues in 
the WW domains interacting with proline rich areas of dSalvador 12,43. However, due to the 
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instability of their protein constructs, the exact interactions that allow for the dSalvador 
homodimer formation were not determined 12. 
Structure of dSalvador and the discovery of the “seatbelt” region 
There has been a lot of work studying the structures of Hippo (MST) and dRassF (RassF) 
and how they interact, but less is known about the structure of dSalvador and the complex it 
forms with Hippo 14,15,39,40. Therefore, our lab endeavored to characterize the protein interactions 
of dSalvador and determine a structure of the protein. Ultimately, work by Leah Cairns, a Ph.D. 
candidate in the lab, revealed a novel structure for dSalvador. Critical to her success was the 
discovery of an extended N-terminal “seatbelt” region in the SARAH domain 38. This 
approximately 20 amino acid residue region was shown to increase the stability of the complex 
between dSalvador and Hippo in vitro, as well as, help stabilize the dSalvador protein, allowing 
for crystallization studies 38.  
Research Questions 
Previous studies have focused on characterizing the Hippo and dRassF interactions of the 
Hippo pathway.  However, now that the structure of dSalvador and its SARAH domain can be 
crystalized and the structure examined, our lab wanted to explore dSalvador and its homodimer 
and heterodimer interactions. As previously mentioned, work has shown that the mammalian 
homologue does not require the C-terminal coiled-coil domain to facilitate homodimers of 
Salvador forming 12. Since this has yet to be demonstrated in the Drosophila protein and because 
the authors were never able to confirm their hypothesis that binding could result from the 
tryptophan in the WW domains interacting with proline rich areas in dSalvador, we are interested 
in examining the requirement of the SARAH and WW domains of dSalvador for dimer 
formation 12. We propose to use binding assays to examine variants of dSalvador lack its 
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SARAH domain, its WW domain, or both to better understand how dSalvador forms its 
homodimer (Figure 13C). 
In the process of determining the structure of the dSalvador/Hippo complex, it was noted 
that the dSalvador/Hippo dimer associates with another dSalvador/Hippo dimer resulting in the 
formation of a dimer of dimers. Facilitating this dimerization was a disulfide bond between 
Hippo and Hippo at cysteine 624 38. Due to the fact that this cysteine was not conserved and the 
relatively small size of the bond, we hypothesized that it was not biologically relevant. Instead, 
we believed that this was an artifact of crystal packing. However, we wanted to confirm, using 
cell based studies, that it did not play a role in activity.  
Some of Leah Cairns’ unpublished data from her Ph.D. work on SARAH domains 
suggests that there is a wide variation in the bond strength of homo and heterodimers formed by 
dRassF, dSalvador and Hippo. In particular, the dimer between dSalvador and Hippo is stronger 
than any of the other hetero- or homo-dimers formed between dRassF, dSalvador and Hippo. 
Knowing this, we wondered if the strength of the interaction between SARAH domains changes 
the regulatory potential of a protein? To test this, we propose interchanging the SARAH domains 
between dRassF, Hippo and dSalvador. To do this, the protein body will be attached to either its 
own SARAH domain or the SARAH domain of one of the other two proteins. A general 
schematic of this plan can be seen in Figure 13B. Ultimately, we hope to perform cell based 
assays to see if you swap a SARAH domain with a different protein, for example the SARAH 
domain of dSalvador with the core protein domain of dRassF, do you alter the strength of its 




Validating the role of the N-terminal extension of Salvador 
In order to validate the significance of the N-terminal extension (seatbelt) region of 
dSalvador’s SARAH domain, a mutant without the seatbelt was compared to the wild type 
protein in a Drosophila based luciferase reporter assay. Using Fugene 6, Gal-4-UAS luciferase, 
Renilla, Gal-4-Dbd-Yki and Hippo were transfected into S2 cells. Either wild type dSalvador 
including the seatbelt or a variant (plasmid code MV, Kavran lab), lacking the seatbelt region, 
were also transfected. In an attempt to improve detection and increase the dynamic range of the 
experiment two concentrations plasmid encoding for Gal-4-Dbd-Yorkie, 50ng or 200ng, were 
used. Following incubation, cells were harvested and cell lysate was used for a luciferase assay. 
A total of five replicates were performed for each experimental treatment. Using Graphpad 
Prism7, normalized luciferase values were plotted and statistical analysis comparing wild type 
dSalvador to the variant without a seatbelt region was performed. In both of the experimental set-
ups using 50ng or 200ng of Yorkie, there was no significant change in luciferase expression (p 
value 0.82, 0.99) (Figure 10). This signifies that in the context of the luciferase assay, the 
seatbelt region does not play a role in regulation Hippo kinase activity. 
Validating the oligomeric state of Hippo:dSalvador  
To confirm that the disulfide bond between Hippo was indeed an artifact of crystal 
packing and not biologically significant, Gal-4-UAS luciferase, Renilla, Gal-4-Dbd-Yki and 
either wild type Hippo or a C624S variant (plasmid code MT, Kavran lab) were transfected into 
S2 cells using Fugene 6. A total of nine replicates were performed across multiple days. Using 
Graphpad Prism7, data normalized in excel were plotted and statistical analysis comparing 
luciferase values for wild type or C624S Hippo were compared to each other. The C624S mutant 
eliminated the potential for the disulfide bond between Hippo dimers. There was no difference in 
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relative luciferase activity between the wild type Hippo and C624S Hippo variant (p value 0.91) 
(Figure 11). This confirms our hypothesis that the disulfide bond is not biologically relevant and 
just an artifact of crystal packing. 
Role of SARAH domains interactions 
 First, we wanted to reproduce published results and confirm the role of dRassF as an 
inhibitor of Hippo activity and establish conditions for a luciferase assay to report on that 
inhibition. Using Fugene 6, Gal-4-UAS luciferase, Renilla, Gal-4-Dbd-Yki, Hippo and dRassF 
were transfected into S2 cells. Three separate experiments were performed for a total of seven 
replicates. In hopes of saturating Hippo, four replicates were run where the amount of plasmid 
encoding dRassf transfected was increased to from 50ng to 200ng. In order to see the inhibitory 
trend, the first four replicates of the experiment have been combined in Figure 12A. and the last 
three replicates in Figure 12B. This was done because of the wide variation in luciferase 
expression levels between experiments. Data normalized in excel were plotted and statistical 
analysis comparing the activity of Hippo in the presence or absence of dRassf was performed 
using Graphpad Prism7. When the experiments from different days were separated as described 
above, the results are statistically significant (p value 0.02, 0.003) but when values across all 
experiments are combined, the range of luciferase expression creates a standard deviation that 
makes all results statistically insignificant (p value 0.27). Increasing the amount of plasmid 
encoding for dRassF did not result in a statistically significant difference between with or 
without dRassF (p value 0.28) (Figure 12C). These results signify that there is an inhibitory 
effect by dRassF on Hippo activity seen through an increase in relative luciferase expression. 
However, further optimization is needed to enhance the dynamic range of the difference. 
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 We are just in the beginning stages of the experiments to test the “hierarchy” of SARAH 
domains. Issues finding the optimal cell based system to express our experimental plasmid 
constructs has proven challenging. However, by transferring our Drosophila genes into a p6a 
mammalian expression vector and expressing the proteins in HEK293T cells we can get 
sufficient protein expression for our studies (Figure 13B). Now that our plasmids do indeed 
express, the proposed experimental set up involves a series of co-immunoprecipitations between 
plasmids that have had their endogenous SARAH domain replaced by a SARAH domain from 
one of the other two proteins. Because we do not know that our constructs will still enable 
normal interactions, we want to validate that the SARAH domains in the variants still facilitate 
binding. Following that, experiments will be conducted to examine binding strength and activity 
levels of our variants through in vitro and cell based assays.  
dSalvador dimerization 
 As previously discussed, the work showing that human Salvador does not require its C-
terminal coiled-coil domain for dimerization has not been demonstrated with the Drosophila 
protein. Additionally, the mechanism by which dimer formation is facilitated in the absence of 
coiled-coil domains was never discovered 12. In order to replicate the experiment with dSalvador 
and determine the exact mechanism of dimer formation, variants lacking the SARAH domain, a 
WW binding domain, or variants lacking both have been cloned into a mammalian, p6a, 
expression vector (Figure 13C). Just as with the SARAH swap, S2 cells could not produce 
suitable protein expression for our experiments so we had to switch to using a mammalian 
expression vector in HEK293T cells. We have confirmed that our plasmids express and the 
proposed experimental setup is outlined in Figure 13C (Figure 13A). Using co-
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immunoprecipitation, we will check to see if the results from human Salvador can be reproduced 




 We used our standard luciferase assay protocol for S2 cells—see Appendix 1 and 
“Optimization of luciferase reporter assay.” 
Western Blot Analysis 
 Protocol adapted from Cairns et. al 2018. HEK293T cells (ATCC) were cultured in 
DMEMF12 (Gibco) supplemented with 5% FBE (VWR) and 2mM L-glutamine at 37 °C and 5% 
CO2. Cells were transfected with a total of 1g of total DNA (p6a plasmids) (Thermo Fisher) 
encoding the indicated proteins using PEI DNA Transfection Reagent (Thermo Fisher) according 
to the manufacturer's protocol. Cells were harvested at 24h following transfection in ice-cold 
RIPA buffer supplemented with 50mM NaF, 1mM Na3VO4, 0.5mM phenylmethylsulfonyl 
fluoride, and Universal Nuclease (Thermo Fisher). Total protein of each experimental condition 
was determined using a bicinchoninic acid assay (BCA assay) (Thermo Fisher). Concentrations 
were calculated by comparing concentrations to a standard curve made from samples of a known 
concentration. Each sample was then standardized to 2.5g per L. 9.5L of cell lysate were 
loaded onto a gel and analyzed by Western blotting using 1:800 dilution of Myc (Santa Cruz, 
number sc40) followed by 1:10,000 dilution of goat α-mouse 800RD (LICOR, number 925-
32210), 1:1000 dilution of HA (Roche, number 11867423001) followed by 1:10,000 dilution of 
goat α-rat 800RD (LICOR, number 925-32219), 1:1000 dilution of FLAG (Sigma, number 
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F1804) followed by 1:10,000 dilution of goat α-mouse 800RD. Blots were scanned on an 
Odyssey IR Imaging System (LI-COR). 
 
Discussion 
The N-terminal extension of dSalvador  
 One of the continued challenges we have faced with the luciferase assay has been its 
inability to tell us anything more than a binary answer. This issue continued to come up with our 
efforts to show that the extended “seatbelt” domain enhances dSalvador/Hippo binding. While 
we were able to demonstrate the increased binding affinity using purified protein, in the context 
of the luciferase assay the difference between wild type and mutant was not pronounced enough 
to make any conclusions. Theoretically, without the “seatbelt” binding between dSalvador and 
Hippo should be weakened and the kinase activity of Hippo should go down. As a result, we 
expected to see an increase in luciferase expression in the no “seatbelt” mutant. There may be a 
slight increase however, again there is not a distinct enough range to parse out the subtle change 
(Figure 11).  
Biological relevance of cysteine 624 in Hippo 
As noted before, during crystallographic studies of the complex between dSalvador and 
Hippo, Leah Cairns noticed that a disulfide bond was being formed between two Hippo proteins 
in dimers at the cysteine 624 residue. Because of this, we needed to validate that this disulfide 
bond did not play a role in Hippo function. In vitro data with purified protein from the lab 
already showed that the removal of the disulfide bond did not interrupt Hippo and dSalvador 
binding, however we needed to confirm that in a cell based setting, that the C624S variant would 
not impact Hippo’s kinase activity. Since there was no change between wild type and variant it 
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was concluded that the disulfide bond that forms between the two Hippo dimers is a result of 
simple crystal packing 38.  
dRassF inhibits Hippo activity 
 It is known that dRassF inhibits Hippo’s kinase activity so it was not unexpected that we 
would be able to see this through the luciferase assay and the result provides a foundation to 
pursue additional experiments with dRassF. Previous work has shown through co-
immunoprecipitation, activity assays and fly based experiments that dRassF preferentially binds 
un-phosphorylated Hippo. This in turn, prevents Hippo from auto-phosphylating itself and 
becoming active 13. Moving forward it will be interesting to see if we can change the ability of 
dRassF to inhibit Hippo activity by attaching a stronger SARAH domain. By attaching a 
SARAH domain with a higher binding strength, for example Salvador’s SARAH domain, we 
may be able to increase the inhibitory effect. 
Future dSalvador and SARAH swap experiments 
 By far the biggest challenge we faced in trying to get the SARAH swap project off the 
ground was finding a way to express our plasmids in Drosophila cells. We had previously 
noticed that raw expression levels for firefly luciferase were 50 to 100-fold lower in S2 cells 
compared to HEK293T cells. While there was still enough signal for the luciferase assay, it 
suggests that in S2 cells there is lower overall protein expression levels and that could explain 
why we were unable to detect protein expression in S2 cells by Western blot. Ultimately, we 
decided to transfer the Drosophila genes into mammalian expression vectors. As soon as we did 
this we were able to get expression at high enough levels to be visualized through Western blot 
(Figure 13). Now that we have expression we can proceed to experiments that examine the 
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Figure 11. Biological significance of Hippo Cyste -
ine 624.
S2 cells were transfected with plasmids encoding 
Renilla, a Gal4-luciferase, Gal4DBD-Yorkie, and 
either wild type or C624S Hippo. Nine experimen -
tal replicates over four experiments were obtained. 
Luciferase values were normalized to the null 
control (luciferase and Renilla). Using Graphpad 
Prism, values were plotted as relative luciferase 
expression, standard error was calculated and 
statistical analysis comparing wild type to C624S 
was performed (p value 0.91, n=9). Error bars 
represent the standard deviations as calculated in 
Prism.
Figure 10. Comparison of dSalvador activity with or withou t its “seatbelt” (SB) region.
A. S2 cells were transfected with plasmids encoding Renilla , a Gal4-luciferase, Gal4DBD-Yorkie, Hippo and either 
wild type (wt) dSalvador or a no SB dSalvador variant usin g Fugene 6. A total of five replicates over two experiments 
were obtained. Luciferase values were normalized to the nu ll control (luciferase and Renilla). Using Graphpad Prism, 
values were plotted as relative luciferase expression, standa rd error was calculated and statistical analysis comparing wt 
to no SB was performed (p value 0.82, n=5). Error bars repr esent the standard deviations as calculated in Prism.
B. Experiment was run as above except, in an attempt to inc rease the dynamic range of the experiment and better visual -


























































































































































Figure 12. dRassF inhibits Hippo kinase activity
A. S2 cells were transfected with plasmids encoding 
Renilla, a Gal4-luciferase, Gal4DBD-Yorkie, Hippo and 
dRassF using Fugene6. After 3 days, the levels of lucifer -
ase were measured. Four replicates over two experiments 
were obtained. Luciferase values were normalized to the 
null control (luciferase and Renilla). Using Graphpad 
Prism, values were plotted as relative luciferase expres -
sion, standard error was calculated and statistical analysis 
comparing Hippo with or without dRassF (p value 0.02, 
n=4). Error bars represent the standard deviations as 
calculated in Prism.
B. To confirm the previous findings, three additional 
replicates were conducted. The same protocol as above 
was used (p value 0.003, n=3).
C. Using the protocol as in A., in an attempt to increase 
the effect of dRassF, the amount of dRassF transfected 




Table 5. dSalvador luciferase plasmids 
For the luciferase assays the following plasmids and concentration were used. Code refers to the 
code that the Kavran Lab has assigned to the plasmid. Complete list of Kavran Lab plasmids can 
be found on the Kavran Lab Google Drive. 
 
Code Plasmid Concentration 
75 Gal4-Dbd-Ykiv5 50ng 
76 Gal-4-pUAST-Luciferase 75ng 
77 pRL-SV40-Renilla 10ng 
66 pAWF-dHpo 50ng 
68 pAWF-dMats 50ng 
69 pAMN-dSav 50ng 
70 pAWF-dWts 50ng 
MT pAc5.2-C624S-Hippo 50ng 
MV pAc2.5-dSav-deltaSB 50ng or 200ng 









Table 6. SARAH swaps plasmids 
The following plasmids were used in the expression test for SARAH swaps. All are based in the 
mammalian p6a expression vector. Code refers to the code that the Kavran Lab has assigned to 
the plasmid. Complete list of Kavran Lab plasmids can be found on the Kavran Lab Google 
Drive. 
 




PB Myc Hippo/Ssb 
PC HA dRassF/Ssb 
PD Flag dSav no sb/ Hippo 
PE Flag dSav no sb/ dRassF 
PF Myc Hippo/dRassF 









Table 7. dSalvador dimerization plasmids 
The following plasmids were used in the expression test for dSalvador dimerization. All are 
based in the mammalian p6a expression vector. Code refers to the code that the Kavran Lab has 





















Optimization of Mammalian Ste20 (MST) variants for crystallographic studies 
Introduction 
Mammalian Ste20 (MST1/2) 
Mammalian Ste20 (MST1/2), is a core kinase within the Hippo pathway. It is the 
homologue to the Drosophila protein, Hippo, and works in tandem with the other core Hippo 
pathway kinase Lats 6,16. Constitutive MST activation and cleavage is critical for maintaining 
regulation of cell growth and proliferation.  Loss of MST function has been shown in in vitro to 
cause rapid and massive cellular overgrowth 17,44. Interestingly, reintroduction of functional MST 
ameliorates this phenotype 17.  The exact mechanism by which this cancer phenotype is sustained 
is not yet known. However, there is some work indicating that in the absence of functional MST, 
tumor necrosis factor alpha does not induce apoptosis possibly leading to this proliferative 
phenotype 16.  
Role of Mob1 in Hippo pathway signaling 
Recently, it has been demonstrated that there is an adapter protein, Mob1, that helps to 
facilitate the signaling cascade between MST and Lats 23.  Auto-phosphorylation of MST is 
required for Mob1 to be recruited to the kinase, but once MST has been phosphorylated, there 
are multiple Mob binding motifs (MBM) on the active kinase that Mob1 can associate with 23,24. 
Mob1 will ultimately bind both MST and Lats. The active MST will phosphorylate Mob1, which 
in turn, enhances Mob1’s ability to activate Lats 23. Activated Lats then regulates YAP through 
phosphorylation and sequestration of the transcriptional co-activator 16,18.  
The structure of MST1/2 
There are five isoforms of MST but for the purpose of our studies, MST2 was used 44. 
The protein is made up of three main parts, a core kinase domain (amino acids (a.a.) 26–327), a 
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flexible linker region (a.a.328–429), and a SARAH domain (a.a 430-480) 15,23,24. Within the core 
kinase domain of MST2 there is an activation loop with a phosphorylation site at threonine 180 
45. Phosphorylation of this threonine leads to the activation of MST2.  The linker region is a 
fairly unstructured region of the protein, approximately 100 amino acids in size. Within this 
region there are multiple phosphorylation sites and MBM, of particular interest to us is the MBM 
at threonine 378 24. This motif has been shown to facilitate binding between MST and Mob1 and 
MST’s subsequent phosphorylation of Mob1 24.  
Research Question 
As demonstrated by previous work, there are multiple sites within the linker region that 
support binding between active MST and Mob123,24. However, the relative affinity and 
importance of the different sites of Mob1 binding is still to be elucidated. Certainly, while there 
have been recent advancements in our understanding of the role of Mob1 and the interaction 
between it and MST, there is still much to be discovered. For that reason, our lab is interested in 
establishing conditions that make it possible to crystalize MST and Mob1 proteins in complex. A 
significant roadblock to this is the linker region attaching the SARAH domain to the core kinase 
domain of MST. The relatively long unstructured region inhibits protein crystallization. 
Therefore, in collaboration with Dr. Thao Tran, I have been working to determine variants of 
MST2 that have a reduced linker region, allowing for crystallization, but that still maintain 
normal function. These variations include removing the linker altogether, removing certain 
phosphorylation sites, and removing the previously published MBM at threonine 378 24. Using 
the optimized luciferase assay we hope to determine the best possible construct of MST for 




Validating the importance of the MST linker region  
Our study of MST began by confirming that linker was indeed required for MST 
functionality. Plasmids encoding for Gal-4-Dbd-TEAD, Gal-4-UAS-luciferas, Renilla, YAP and 
Hippo pathway components were transfected into HEK293T cells using Lipofectamine 2000. 
Within the context of our experiment, wild type MST or MST no linker (plasmid code GY, 
Kavran lab), were transfected in addition to Salvador, Mob1 and Lats. As a negative control for 
MST activity we used a kinase inhibited version, D146N, of MST (plasmid code IH, Kavran 
lab). A total of four replicates were obtained from two separate experiments. Using Graphpad 
Prism7, values were plotted and statistical analysis comparing the MST variant without a linker 
region to wild type MST was performed (p value 0.0001) (Figure 14B). In the absence of the 
linker, MST losses all function, with luciferase expression levels returning to the same levels as 
the positive control, luciferase, Renilla and YAP (Figure 14B). 
 Next, in an attempt to find a variant where the linker region was reduced instead of 
removed completely, we tested two MST variants with parts of the linkers removed. A schematic 
of these two constructs can be seen in Figure 14A. Following the same procedure as before, we 
tested to truncated version of MST, one with the amino acids from NKS...PDN (plasmid code 
EZ, Kavran lab) the other with amino acids from SHT...VIN and from NKS...PDN (plasmid code 
FA, Kavran lab) removed. Statistical analysis using Graphpad Prism7 revealed that there was no 
statistically significant difference in luciferase expression between wild type MST and the two 
variants (Figure 14B) (p value 0.99, 0.99). 
Validating the importance of MBM at threonine 378 
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 Interested in understanding the importance of the MBM described by Ni et al. we tested a 
MST variant with the published MBM removed (plasmid code GX, Kavran lab) against wild 
type MST. Again, following the same procedure, we performed a luciferase assay to test MST 
function. Similar to the two linker variants, statistical analysis performed using Graphpad Prism7 





 Standard mammalian luciferase protocol was followed (Appendix 1). 
 
Discussion 
A minimal MST linker region is required for function 
 As previously discussed, the luciferase reporter can only give a binary answer. This 
means that in the context of our MST2 experiments the only information that we obtained was 
whether or not a mutant was functional. Unfortunately, the luciferase assay was not able to parse 
out more muted changes in levels of activity. The linker region contains multiple 
phosphorylation sites within it and is believed to play a role in the recruitment and binding of 
Mob1 15,23,24. The results of the luciferase assay further support the idea that at least a minimal 
region of the linker is required to maintain normal kinase activity (Figure 14B). The two 
experimental mutants of MST2 that had phosphorylation sites within the linker region removed 
proved to retain wilt type function (Figure 14B). This might suggest that the specific 
phosphorylation sites are not critical for function. However, the more likely explanation is that 
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since there are so many phosphorylation sites within the linker region, there is a certain level of 
redundancy that allows for the kinase to retain functionality.  
The MBM at threonine 378 is not required for function 
While Ni et al. only highlight the MBM at threonine 378, later work by Couzens et. al. 
show that in fact, there are many MBMs on active MST. Therefore, it is not unexpected that the 
MBM variant retained its wild type activity (Figure 14B). Here, the limitation of the luciferase 
assay may be a confounding factor as MST2 activity might be partially reduced by loss of the 
MBM. However, the other MBMs more than certainly provide a redundancy that allows for 
Mob1 and MST to still bind 23. Further experiments are needed to examine other MBMs and 
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Figure 14. Determining the minimal functional unit of MST  
A. Schematic of wild type and experimental variants of MST2. Each of the schematics correlates to the 
plasmid used in the luciferase assay. Green ovals represent the core kinase domain of MST. The green 
rectangle represents the SARAH domain. The black line represents the linker region with black dots 
representing phosphorylation sites. Mon binding motifs are represented by MBM in blue below the 
linker region. Red “x” represents inhibition of kinase activity .
B. Using Lipofectamine 2000, Gal4Dbd-Tead, Gal4-Luciferase, Renilla, YAP, hSav, Mob, Lats, wild 
type (wt) and mutant MST2 variants were transfected into Hek293T  cells. After 48 hours cells were 
harvested and lysed. A total of four replicates from two experiments were obtained. Luciferase data was 
normalized to the null control (luciferase and Renilla). Using Graphpad Prism, values were plotted as 
relative luciferase expression, standard error was calculated and statistical analysis comparing wild type 





Table 8. MST variant plasmids 
For the luciferase assays the following plasmids and concentration were used. Code refers to the 
code that the Kavran Lab has assigned to the plasmid. Complete list of Kavran Lab plasmids can 
be found on the Kavran Lab Google Drive. 
Code Plasmid Concentration 
90 Gal4-UAS-Luciferase 100ng 
91 pRL-SV40-Renilla 10ng 
122 p2xFlagCMV2-Yap2 25ng 
93 Gal4-Dbd-TEAD4 75ng 
94 pcDNA-HA-Mst2 75ng 
95 pcDNA-HA-Sav 75ng 
96 pcDNA-HA-Mob 75ng 
97 pcDNA-Myc-Lats 75ng 
EZ pcDNA-MST-deltaL1 75ng 
FA pcDNA-MST-deltaL2 75ng 
GY pcDNA-MST-noL 75ng 
GX pcDNA-MST-noMBM 75ng 







Minimal Functional Unit of Large tumor suppressor (Lats) 
Introduction 
Large tumor suppressor 
 Along with MST, Lats makes up the central cassette of the Hippo pathway. It plays a 
critical role in the regulation of proliferation and growth. This is because its kinase activity is 
responsible for phosphorylating the target of the Hippo pathway, YAP 8,19,46. Loss of Lats 
function is disastrous and can lead to a severe overgrowth phenotype, carcinogenesis and death 
in mice 3,32. While there is no evidence yet that Lats drives any human carcinomas, its clear role 
in the progression of cancer in mice demonstrates the importance of understanding the kinase, its 
activity, and the mechanism by which it is activated better.  
Recent studies support that Lats complexes with both Mob1 and MST and these events 
are required for its activiation24.  When Lats associates with active MST, MST phosphorylates 
Lats on threonine 1079 located in the hydrophobic motif of Lats. The phosphorylation of 
threonine 1079 subsequently stimulates the auto-phosphorylation of serine 909 in the activation 
loop 19,46. Additional work has elucidated a Mob binding motif within the N-terminal region of 
Lats 21,47.  In order for Mob1 to bind to this motif it must undergo phosphorylation by MST. The 
exact mechanism by which phosphorylation of Mob1 occurs and then promotes Lats binding is 
not known. However once Mob1 interacts with binding motif on the N-terminal region of Lats, it 
assists in regulating Lats activation 21,24. Ultimately, once Lats is activated it can proceed to 
phosphorylate its target, YAP. This in turn inhibits YAP’s ability to translocate to the nucleus 
and prevents the transcription of pro-growth genes 47.   
Research Question 
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While recent works have shed light on the mechanism by which Lats is activated, there is 
still much more to learn. Our lab is particularly interested in studying Lats as both an individual 
protein and in a complex with its binding partner, Mob1. To this point crystallographic studies 
have focused on the N-terminal Mob binding domain and not the entire protein 21,47. This may be 
due to the fact that Lats is predicted to be relatively large and unstructured. In particular, outside 
of the Mob binding domain, the N terminal region is believed to be relatively unordered, making 
the entire protein hard to isolate. Our lab hypothesized that because of the lack of homology on 
the N- and C-terminal region of Lats, significant amounts of amino acid residues could be 
removed without changing its kinase activity. By doing this, the protein could more easily be 
isolated. The protocol that a graduate student in the lab, TJ Koehler, has proposed to use in order 
to purify Lats relies on the cleavage of a C-terminal intein tag. This type of cleavage results in a 
cysteine scar. In order to validate the kinase activity of these smaller versions of Lats, luciferase 
reporter assays were used to compare activity against wild type. Additionally, mutants were 
made that had a cysteine inserted, similar to the product of intein cleavage, to check if the 




 The N-terminal region of Lats, as previously discussed, is predicted to be large and 
unstructured. This ultimately plays a large role in the challenges of crystalizing the entire Lats 
protein. With that in mind we compared variants of Lats with truncations to the N-terminus that 
still retained the N-terminal Mob binding domain with wild type Lats. Using Lipofectamine 
2000, HEK293T cells were transfected with Gal-4-Dbd-TEAD, Gal-4-UAS-luciferas, Renilla, 
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YAP and Hippo pathway components. A kinase dead, D827N, version of Lats was used as a 
negative control (plasmid code KE, Kavran Lab). A total of four replicates from two distinct 
experiments were collected. Values were normalized to the null control, luciferase and Renilla. 
Using Graphpad Prism7, luciferase expression values were plotted and appropriate statistical 
analysis comparing variants to wild type Lats performed. Following the kinase dead column, the 
N-terminal length of the variants increases from left to right (Figure 15A). None of the N-
terminal truncations show a significant difference in luciferase expression compared to wild 
type. However, the most severe truncation does show a much higher degree of variation between 
replicates. 
C-Terminal Truncations 
 Compared to the N-terminus, the length of the C-terminus before the conserved amino 
acid sequence of the kinase domain of Lats is reached, is much smaller. Therefore, truncations of 
the C-terminus were far less aggressive than the N-terminus. In the same way as described above 
variants of the C-terminus were tested against wild type Lats. Following the column for kinase 
dead, the experimental variants increase in C-terminal length from left to right (Figure 15B). 
Statistical analysis using Graphpad Prism, comparing wild type to C-terminal variants shows not 
significant difference between any column. Similar to the N-terminal truncations, the most 
aggressive truncation does show a higher degree of variation and is trending towards luciferase 
expression similar to that of the kinase dead control. 
Cysteine Addition 
 Because the protocol for intein tag cleave leaves a cysteine scar, we wanted to determine 
if the insertion of a cysteine would have any impact on the activity of Lats. Within the C-
terminus we looked for regions where the insertion of the cysteine would be far enough away 
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from the threonine that gets phosphorylated that it would not interfere with activation. 
Additionally, candidates for areas of insertion had to be in sequence areas that did not share 
homology with the Drosophila orthologue, Warts, as those areas are presumed to be part of the 
core kinase domain. Based upon these parameters, two variants were made one, H1071C 
(plasmid code HC, Kavran lab) and the other, A1075C (plasmid code IB, Kavran lab). Following 
the standard protocol as described above these two variants were compared to wild type Lats. 
Statistical analysis revealed that there was no difference in luciferase expression between either 
variant and wild type (Figure 15C) (p value 0.99, 0.99). These results imply that the addition of a 








Determination of Lats minimal functional unit 
 Ultimately, the results of our luciferase assays indicated that from the whole 1130 amino 
acid Lats protein, the region from amino acids 621 to 1085 are critical for activity and was 
defined as the minimal function unit (MFU).  Using the data from the luciferase assay combined 
with activity assays performed by another master’s student, Yoo Jin Kim, TJ has selected various 
forms of the MFU to clone into expression vectors. He will use these clones to express Lats and 
hopefully purify a well-behaved protein that can be used for crystallographic studies.  
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The cysteine scar from intein cleavage will not change Lats activity 
Since the cysteine residue proved to have no impact on Lats function, TJ decided to 
proceed with the intein tag protocol in order to isolated functional and well behaved Lats protein. 
Now that Lats has been purified on its own, further work to crystalize it can proceed. This 
project is in its beginning stages and there is still much to be done but the isolation of Lats 







































































































































































Figure 15. Defining the minimal functional unit of Lats2
A. Using Lipofectamine 2000, Gal4Dbd-Tead, Gal4-Lu-
ciferase, Renilla, YAP, hSav, Mob, MST, wild type (wt) 
and N terminal variants of Lats2 were transfected into 
Hek293T cells. After 48 hours cells were harvested and 
lysed. A total of four replicates over two experiments 
were obtained. Luciferase data was then normalized to the 
null control (luciferase and Renilla). Using Graphpad 
Prism, values were plotted as relative luciferase expres -
sion, standard error was calculated and statistical analysis 
comparing wild type to experimental Lats variants (p 
value 0.99, n=4). The gradually increasing right triangle 
represents the increasing length of the N-terminus.
B. Following the above protocol C terminal Lats variants 
were analyzed (p value 0.99 n=4). The gradually increas-
ing right triangle represents the increasing length of the 
C-terminus.
C. Using the same protocol Lats variants, “HC” and “IB” 































































































Table 9. C-terminal variant plasmids 
For the luciferase assays the following plasmids and concentration were used. C-terminal lengths 
are listed from shortest at the top to longest at the bottom Code refers to the code that the Kavran 
Lab has assigned to the plasmid. Complete list of Kavran Lab plasmids can be found on the 
Kavran Lab Google Drive. 
Code Plasmid Concentration 
90 Gal4-UAS-Luciferase 100ng 
91 pRL-SV40-Renilla 10ng 
122 p2xFlagCMV2-Yap2 25ng 
93 Gal4-Dbd-TEAD4 75ng 
94 pcDNA-HA-Mst2 75ng 
95 pcDNA-HA-Sav 75ng 
96 pcDNA-HA-Mob 75ng 
97 pcDNA-Myc-Lats 75ng 
KE pcDNA-Lats-D827N 75ng 
HE pcDNA-Lats-Ctermtrunc 75ng 
HB pcDNA-Lats-Ctermtrunc 75ng 
FW pcDNA-Lats-Ctermtrunc 75ng 
FV pcDNA-Lats-Ctermtrunc 75ng 
FU pcDNA-Lats-Ctermtrunc 75ng 




Table 10. N-Terminal variant plasmids 
For the luciferase assays the following plasmids and concentration were used. N-terminal lengths 
are listed from shortest at the top to longest at the bottom. Code refers to the code that the 
Kavran Lab has assigned to the plasmid. Complete list of Kavran Lab plasmids can be found on 
the Kavran Lab Google Drive. 
Code Plasmid Concentration 
90 Gal4-UAS-Luciferase 100ng 
91 pRL-SV40-Renilla 10ng 
122 p2xFlagCMV2-Yap2 25ng 
93 Gal4-Dbd-TEAD4 75ng 
94 pcDNA-HA-Mst2 75ng 
95 pcDNA-HA-Sav 75ng 
96 pcDNA-HA-Mob 75ng 
97 pcDNA-Myc-Lats 75ng 
KE pcDNA-Lats-D827N 75ng 
FZ pcDNA-Lats-Ntermtrunc 75ng 
GJ pcDNA-Lats-Ntermtrunc 75ng 
GN pcDNA-Lats-Ntermtrunc 75ng 
GI pcDNA-Lats-Ntermtrunc 75ng 





Table 11. cysteine addition plasmids 
For the luciferase assays the following plasmids and concentration were used. Code refers to the 
code that the Kavran Lab has assigned to the plasmid. Complete list of Kavran Lab plasmids can 
be found on the Kavran Lab Google Drive. 
Code Plasmid Concentration 
90 Gal4-UAS-Luciferase 100ng 
91 pRL-SV40-Renilla 10ng 
122 p2xFlagCMV2-Yap2 25ng 
93 Gal4-Dbd-TEAD4 75ng 
94 pcDNA-HA-Mst2 75ng 
95 pcDNA-HA-Sav 75ng 
96 pcDNA-HA-Mob 75ng 
97 pcDNA-Myc-Lats 75ng 
KE pcDNA-Lats-D827N 75ng 
HC pcDNA-Lats-H1071C 75ng 


















 Ultimately, I was able to establish a very reliable and reproducible protocol for using a 
luciferase reporter assay to test different protein constructs that our lab was interested in 
studying. However, there are a few limitations to our protocol. Most notably, all of the Hippo 
pathways core proteins and adapters must be transfected into our system. This means that it is 
impossible to study an individual protein’s activity through luciferase. Rather our protocol 
allows us to see how it functions within the context of the entire pathway. Additionally, over the 
optimization process we came to realize that as a result of our dynamic range and the high level 
of variability between assays, our protocol cannot describe a range of activity levels, instead it 
can only provide a binary result. 
 We were able to get some great preliminary results in our Lats and MST studies and 
published our work on Hippo. This was really exciting but moving forward there is a lot more 
work to do. There are still aspects of our protocol that can be further refined and exploring 
alternative cell types may be beneficial in helping answer our research questions. Recently, we 
discovered that basal levels of Hippo pathway expression in our HEK293T cells is relatively 
high. This has confounded some experiments and may contribute to the overall variability in our 
luciferase assays.  
In addition to challenges with our mammalian cells, our Drosophila cells have continued 
to be unreliable in producing results. We have explored different Drosophila cell types to no 
avail. This has proved to be one of the biggest roadblocks to pushing Drosophila protein projects 
forward.  While we have worked around this by transferring proteins to mammalian expression 
vectors, this method comes with its own confounding factors. To best study our proteins of 
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interest it will be a priority of upcoming work to optimize a Drosophila cell based system that is 
both function for luciferase reporter assays and immunoprecipitation studies. 
Originally, we planned to have the SARAH domain studies as the largest part of this 
master’s thesis. We were really excited about learning more about the hierarchy of SARAH 
domains and following up on previous studies of dSalvador’s SARAH domain. However, due to 
the unforeseen issues setting up the luciferase assay and continued struggles with Drosophila cell 
work, we are only now ready to proceed with these experiments. In the last month of my time 
here, I will work on the dSalvador SARAH dimerization studies but following students will have 
to complete the SARAH swap work. 
 The last two years of work has been an incredible learning experience and helped 
tremendously in reinforcing biochemical and molecular biology principles and techniques. I am 
incredibly grateful for the opportunity to continue to pursue research and in my next steps I hope 
to stay connected to oncology studies and bench work. Enough cannot be said for the 
environment that Dr. Kavran has created in her lab. The collaboration and comradery between 
master’s students, doctoral students and post docs is second to none and made the last two years 
that much more enjoyable. Dr. Kavran has challenged me intellectually and academically, 
pushed me to be more successful and most importantly, has been the best mentor I could have 









Complete protocol for luciferase reporter assay 
The following is the basic protocol for the luciferase reporter assay in both Drosophila and 
mammalian cells. 
Preparation of Luciferase Reaction Substrate 
Thaw Luciferase Assay Reagent II (LARII) (Promega Corporation) Stop & Glo® Reagent 
(Promega Corporation) and add appropriate substrate to each buffer following manufacturer’s 
directions. Dissolve all of the dry LAR II substrate in 10mL of the LAR II buffer provided. Mix 
the entire Eppendorf of Stop & Glo® substrate with the 10mL bottle of the Stop & Glo® buffer. 
Make sure not to cross-contaminate the LARII and the Stop & Glo® reagents as this will render 
them useless. Once mixed, aliquot out 1mL aliquots of each diluted substrate mix into Eppendorf 
tubes and freeze at -80oC.  
Cell culture and preparation of cell lysate 
General information 
In order to account for transfection variability each experiment should be done in either 
duplicate or triplicated depending on the number of wells you have available. These replicates 
should be all transfected from the same master mix of experimental DNA and transfection 
reagent to maintain consistency. In order to be able to use the statistical analysis tool in Prism a 
minimum of two replicated from two separate experiments, giving you an n=4 is needed. 
However, for publication, two or three replicates from four separate experiments, giving you an 
n=8-12 is generally accepted. This amount off data points allows for a high degree of certainty 
when drawing any conclusions from the data. 
Cell Culture 
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Mammalian cells, HEK 293, 293T and 293FT were cultured in Dulbecco's Modified 
Eagle Medium (Gibco) with 2mM L-Glutamine (Gibco) and 5% heat inactivated Fetal Bovine 
Serum (FBS) (VWR). After research and additional testing, we determined that a synthetic form 
of FBS could be used in culture media and switched the lab over to FBEssence (FBE) (VWR). 
Culture chamber was maintained at 37oC with 5% CO2. All mammalian Luciferase transfections 
were performed in 12 well cell culture plates seeded with 5*10^4 cells in 1mL of culture media. 
Cells were seeded and transfected on the same day for all mammalian reactions. After 48 hours 
cells were harvested and lysed. Cell lysate was then used for the luciferase assay. 
Drosophila S2 cells were cultured in Schneider’s Insect Medium (Gibco) with 10% heat-
inactivated FBS. S2 cells cannot be grown in media with FBE. The culture chamber was 
maintained at 28oC without CO2. All Drosophila luciferase experiments were performed in 12 
well cell culture plates seeded with 1*10^5 cells in 1mL of culture media. Cells were seeded on 
day 0 and transfected on day 2. 72 hours after transfection cells were harvested and lysed.  
For more information about cell culture see the protocols for both mammalian and 
Drosophila cell culture on the Kavran Lab Google drive. 
Mammalian cell transfection, incubation and harvesting protocol 
Day 1. 
Plate 5*10^4 HEK293T cells per well in a twelve well plate in 1mL of DMEMF12 with 5%FBE 
and 2mM L-glutamine. In Eppendorf tube mix 25L of OptiMEM (Gibco) reagent with 1g of 
total DNA per well. In a separate Eppendorf tube mix 25L of OptiMEM with 2L of 
Lipofectamine 2000 reagent. The DNA: Lipofectamine ratio should always remain 1:2. Mix 
DNA complex with Lipofectamine complex vigorously using the vortex and incubate at room 
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temperature for 5-10 minutes. Add dropwise the 50L of the reaction mixture to each well. Swirl 
plate to make sure transfection mixture disperses evenly in well. Return to incubator. 
DNA amounts (per well) for optimal Luciferase assay: Refer to Table 2 on page 34. 
Day 2. 
Remove media with transfection mixture. Lipofectamine 2000 is highly toxic to the cells so 
media must be replaced on the cells no later than 24 hours post transfection. Replace with 1mL 
of fresh supplemented DMEM media. This must be done gently as cells have a tendency to lift 
off the plate if added in too harsh a matter. Under the microscope the wells should be 
approximately 40-50% confluent. 
Day 3. 
Each well should be 80-100% confluent under the microscope. However, transfecting the cells 
does make them clump so confluency may appear lower or cells may have lifted off while 
changing media. As long as the wells are over 50% confluency there should be enough cells to 
detect luciferase signal. Aspirate media from each well and gently wash with 1mL of Phosphate 
Buffered Saline (PBS). Aspirate PBS making sure not to disrupt cells. While washing with PBS, 
thaw 5x Passive Lysis Buffer (PLB) (Promega Corporation) and 1mL aliquots of LARII and 
Stop & Glo® substrates (Promega Corporation). Dilute 5x PLB to 1x concentration in PBS. Add 
150L of 1x PLB to each experimental well. Lyse cells at room temperature on a rocker for 10 
min. While cells are lysing, dilute each 1mL Eppendorf of LARII and Stop & Glo® reagents 1:3 
with PBS in to their own 15mL tubes. Once cells are lysed, you can either perform the 
experiment or freeze lysate at negative twenty degrees. To run luciferase assay load 10L of 
lysate into the wells of a ninety-six well white plate making sure to skip the first two wells of the 
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first row in order to prime injectors on luminometer. At this point you are ready to move to the 
luminometer and detect luciferase signal. 
Drosophila cell transfection, incubation and harvesting protocol 
Day 0. 
Plate 10^5 S2 cells per well in a twelve well plate in 1mL of Schneider’s Drosophila media with 
10% FBS.  
Day 2. 
In Eppendorf tube mix 25L of serum free Schneider’s Drosophila media 0.5g of total DNA 
per well. In a separate Eppendorf tube mix 25L of serum free media with 2L Fugene6 reagent. 
The DNA: Fugene6 ratio should always remain 1:2. Mix DNA complex with Fugene 6 complex 
vigorously using the vortex and incubate at room temperature for 15-20 minutes. Add the 50L 
of the reaction mixture dropwise to each well. Swirl plate to make sure transfection mixture 
disperses evenly in well. 
DNA amounts (per well) for optimal Luciferase assay: Refer to Table 4. Page 36 
Day 5. 
Remove media and cells from each well and spin down in an Eppendorf tube at 1200*g’s for 5 
minutes at room temperature. Gently wash pellet with 1mL of Phosphate Buffered Saline (PBS) 
and spin again. Aspirate PBS making sure not to disrupt cells. While washing with PBS, thaw 5x 
Passive Lysis Buffer (PLB) (Promega Corporation) and 1mL aliquots of LARII and Stop & 
Glo® substrates (Promega Corporation). Dilute 5x PLB to 1x concentration in PBS. Add 150L 
of PLB to each experimental Eppendorf. Lyse cells at room temperature on a rotating shaker that 
fits 1.5mL Eppendorf tubes for 10 min. While cells are lysing, dilute 1mL aliquots of LARII and 
Stop & Glo® reagents 1:3 with PBS in their own 15mL tubes. Once cells are lysed, you can 
 74 
either perform the experiment or freeze lysate at negative twenty degrees. To run luciferase assay 
load 10L of lysate into the wells of a white ninety-six well plate making sure to skip the first 
two wells of the first row in order to prime injectors on luminometer. At this point you are ready 
to move to the luminometer and detect luciferase signal. 
Luminometer Protocol 
1. On the home-screen of HP laptop attached to the “Synergy H1” luminometer open the 
“Gene 5 2.0” program. 
2. Under the “read now” tab open “Kavran Lab Brendan” protocol 
3. When the protocol is opened it will automatically take you to the well selection pop-up. 
Exit the pop-up. 
4. Open the “Synergy H1” instrument icon on the top middle of the page (it is a picture of 
the luminometer). 
5. In the instrument icon, select the dispenser tab 
6. Put each injector into the bottles of water provided (yellow tape with injector 1, red tape 
with injector 2) 
7. In the dispenser tab, set dispense rate to 300 L/sec, and dispense amount to 1000L. 
8. Prime 1mL of water in both dispenser 1 and 2, making sure that you put the priming plate 
in the plate holder to catch any excess liquid. 
9. Replace the water bottles with the tubes of LARII and Stop & Glo®. Firefly should be 
put with dispenser 1 and Stop-and-Glow with dispenser 2. 
10. Prime 1mL of reagent into each dispenser 
11. Once primed, replace priming plate with you 96 well experimental plate. Make sure that 
the “A1” corner is aligned properly in the plate holder. 
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12. Exit instrument reader control pop-up 
13. Select the green circle for “read now” in the top icon bar 
14. Using you mouse highlight all the wells that you want to be read and press start 
15. After run save experiment to an external hard drive 
16. To export click the export icon on the top icon bar and save the excel spreadsheet to and 
external drive. DO NOT save to the computer, the Wang Lab regularly deletes saved 
results for some reason. 
17. Remove your 96 well plate and replace it with priming plate. Also remove any leftover 
substrate reagent and save at negative twenty degrees for your next experiment. 
18. Follow the instructions on the luminometer for cleaning using the provided water and 
ethanol. 
Luciferase Normalization 
The results from the luminometer are raw intensity values and do not immediately give us 
much information about our proteins of interest. In general, for HEK293T cells you should 
expect to see Renilla values in the mid 10^5 and firefly values from the high 10^4 to the low 
10^5. For S2 cells, both firefly and Renilla values should fall between the mid 10^3 to the mid 
10^4. If wells give an overflow value you will either have to re-run the entire plate with all the 
samples equally diluted or, if you have enough replicates, you can choose to exclude the well. In 
order to better understand the data, we first divide the raw firefly luciferase value by the 
corresponding Renilla luciferase value for each replicate. This will be called the “ratio”.  
Next, the ratio values for the positive control and our experiments will be divided by the 
ratio value of the null control, which in our protocol will be cells transfected with luciferase and 
Renilla alone. The ratio value from the first well of the null control duplicate will be used to 
 76 
divide the ratio value for the first well of the positive control duplicate and continuing to the 
experimental wells. The ratio value of the second well of the null control will be used in the 
same manner. The results of this should give the null control a value of one with the positive 
control and experiments with some positive number which is the relative luciferase activity. 
To plot the data, copy the fold values from excel into the appropriate graph setup, either 
XY, column, or grouped in Prism. I prefer column graphs and they are relative easy to work with 
once in Prism. In Prism, the program will automatically make a graph. You can edit the graph to 
make it look like how you prefer i.e. columns, dot plot etc. Prism will also automatically 
calculate the standard deviation and use that to make error bars. To obtain p values use the 
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